Hybio Pharmaceutical's H1 revenue continues to decline. Are active pharmaceutical ingredients becoming a 'lifesaver' for large orders? | Interpretations

①In the first half of this year, the revenue decline trend of Hybio Pharmaceutical has not been stopped, and the net profit loss has narrowed to some extent; ②The revenue of the formulation sector continues to decline due to the impact of block orders for main products, and the revenue contribution of the active pharmaceutical ingredient sector has become the first; ③In the first half of this year, Hybio Pharmaceutical has made some efforts to alleviate the cash flow.

cls.cnAug 23 08:58 ET

The suspected pollution of Erkang Pharmaceuticals' Cambodian factory was evicted due to a local request and an announcement will be made later

Serious pollution

Wallstreet NewsAug 15, 2023 05:37 ET

Ligand Pharmaceuticals Collaborates With China Resources Double-Crane to Develop Oral COVID-19 Therapeutic

MT NewswiresOct 21, 2021 10:33 ET

Ligand Pharmaceuticals and China Resources Double-Crane ink collaboration agreement

Seeking AlphaOct 21, 2021 09:12 ET

On September 16, six companies announced positive results: Angel Yeast plans to establish a joint venture with Neubao Foods to develop the baby snack food business

　　Yutong Technology announced that it plans to spend 100 million to 200 million yuan to repurchase shares of Yutong Technology. The company plans to repurchase the company's shares at a price of no more than 41.19 yuan/share, with a repurchase amount of not less than 10 million yuan and no more than 20 million yuan. All of the shares repurchased will be used for employee stock ownership plans or equity incentive plans. Angel Yeast announced that it plans to establish a joint venture with Neubao Foods to develop the baby snack food business Angel Yeast. In order to promote the rapid development of the baby snack food business segment, Angel Yeast plans to establish a joint venture with Kang Helong, Hubei Neubao Food Technology Co., Ltd. (with industry and commerce)

證券之星Sep 15, 2021 20:57 ET

On September 15, 10 companies including Angel Yeast and Yan'an Bikang announced favorable results

　　1. Angel Yeast: Angel Yeast announced that it intends to establish a joint venture with Kang Helong to develop the baby snack food business. In order to promote the rapid development of the baby snack food business segment, Angel News plans to establish a joint venture with Kang Helong. The joint venture will seek new opportunities for development in the field of infant snack food as a holding subsidiary specializing in the development of products related to the snack food industry by Angel Newt. 2. Poinsettia: The wholly-owned subsidiary obtained the bromhexine hydrochloride injection registration certificate. The wholly-owned subsidiary obtained the bromhexine hydrochloride injection registration certificate. 3. Qianjing Garden: Won the bid 67

證券之星Sep 15, 2021 06:01 ET